Lisa Arkin is a Dermatology physician affiliated with University of Wisconsin–Madison. OpenAlex indexes 111 publications with 1,763 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography
Sponsor: University of Wisconsin, Madison
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli LillyProgram year20251 paymentResearch$30,094openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year20259 payments$18,801openpaymentsdata.cms.gov ↗
- AmgenProgram year20251 paymentResearch
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
40%Corticosteroid24.2%Triamcinolone Acetonide100%Part D≥16 patientsInterleukin-4 Receptor alpha Antagonist15.8%Dupixent Syringe100%Part D<11 patientsSensory organs
22.1%Corticosteroid22.1%Clobetasol Propionate100%Part D≥17 patientsAnti-infectives
21.1%Azole Antifungal21.1%Ketoconazole100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial
Journal of the American Academy of Dermatology
2024 - SARS-CoV-2 brainstem encephalitis in human inherited DBR1 deficiency
The Journal of Experimental Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Lucey, MD
University of Wisconsin–Madison
Paul Rutecki, MD
University of Wisconsin–Madison
Justine Bruce, MD
University of Wisconsin–Madison
Mark Albertini, MD
University of Wisconsin–Madison
Robert Modlin, MD
University of California, Los Angeles
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Joel Gelfand, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”